Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer

Defining the optimal neoadjuvant strategy in early-stage and locoregional (N2) oncogenic-driven lung cancer remains a major challenge for the scientific community. Whereas significant advances have been achieved with the use of personalized medicine and targeted therapies in advanced stages, we are...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes, Roxana, Reguart, Noemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Articles on Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867758/
https://www.ncbi.nlm.nih.gov/pubmed/33569340
http://dx.doi.org/10.21037/tlcr-20-780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867758/
https://www.ncbi.nlm.nih.gov/pubmed/33569340
http://dx.doi.org/10.21037/tlcr-20-780

Ejemplares similares